<DOC>
	<DOCNO>NCT01045421</DOCNO>
	<brief_summary>This open-label , multicenter study phase 1 dose escalation portion 2-stage , phase 2 portion , investigate MLN8237 ( alisertib ) patient advanced nonhematological malignancy .</brief_summary>
	<brief_title>Alisertib Adults With Nonhematological Malignancies , Followed Alisertib Lung , Breast , Head Neck Gastroesophageal Malignancies</brief_title>
	<detailed_description>Following determination Recommended Phase 2 Dose ( RP2D ) schedule ( Phase 1 ) , 20 response-evaluable patient 5 tumor indication enrol ( Phase 2-Stage 1 ) . An interim analysis determine tumor indication proceed enroll additional 25 patient ( Phase 2-Stage 2 ) evaluate Overall Response Rate ( ORR ) secondary endpoint .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : 18 year old Histologically cytologically confirm metastatic and/or advance solid tumor ( Phase 1 ) Phase 2 require Nonsmall cell lung cancer ( NSCLC ) ; Smallcell lung cancer ; Breast adenocarcinoma ( female patient ) ; Squamous cell cancer head neck ( HNSCC ) ; Gastroesophageal adenocarcinoma Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception abstain heterosexual intercourse Male patient agree practice effective barrier contraception agree abstain heterosexual intercourse Voluntary write consent Wiling comply schedule visit , treatment plan , laboratory test trial procedure Measurable disease ( Phase 2 ) Patients meet follow exclusion criterion enrol study : Female patient pregnant lactate Serious medical psychiatric illness could interfere protocol completion Receipt 2 previous cytotoxic chemotherapeutic regimen ( 4 previous regimen breast cancer ) . There limit number prior noncytotoxic therapy Prior treatment Aurora Atargeted agent , include MLN8237 Prior treatment highdose chemotherapy Prior allogeneic bone marrow organ transplant Antineoplastic therapy , radiation therapy experimental therapy 21 day prior first dose MLN8237 Symptomatic brain metastasis Radiotherapy great 25 % bone marrow Diagnosis treatment another malignancy within 2 year precede first dose study drug except nonmelanoma skin cancer situ malignancy completely resect Myocardial infarction within 6 month enrollment Uncontrolled cardiovascular condition Major surgery within 14 day first dose MLN8237 Active infection require systemic therapy , serious infection Inability swallow oral medication Known history human immunodeficiency virus ( HIV ) infection , hepatitis B , hepatitis C Patients require full systemic anticoagulation History uncontrolled sleep apnea syndrome Treatment clinically significant enzyme inducer within 14 day prior first dose MLN8237 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>SCLC</keyword>
	<keyword>HNSCC</keyword>
</DOC>